Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OCULAR THERAPEUTIX, INCOCUL · Entity 273 | Director · See Remarks | August 24, 2026 | August 26, 2026 |
| Whitehawk Therapeutics, Inc.ARPO · Entity 6074 | Director | June 30, 2021 | July 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OCULAR THERAPEUTIX, INC
Report date August 24, 2026 · Filed August 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,525,429 |
Reported balance
After 2026-08-24 transaction · row 1
1 source rowRow 1 · 2026-08-24 · Sale · Disposed 21,649 · Balance 2,525,429 F1: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on August 22, 2026. The sales do not represent a discretionary trade by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.6400 to $10.9000, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. |
| Common StockSEC Table I · non-derivative | IndirectBy spouse | 0 |
Reported balance
After 2026-08-25 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-08-25 · Gift · Disposed 50,092 · Balance 0 F3: On August 25, 2026, the reporting person's spouse transferred 50,092 shares to the Pravin Dugel 2024 Irrevocable Trust (the "Trust") for no consideration. The reporting person is trustee of the Trust and sole beneficiary of the Trust during his lifetime. The reporting person remains the beneficial owner of the securities held by the Trust. |
| Common StockSEC Table I · non-derivative | IndirectBy Pravin Dugel 2024 Irrevocable Trust | 744,903 |
Reported balance
After 2026-08-25 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-08-25 · Gift · Acquired 50,092 · Balance 744,903 F3: On August 25, 2026, the reporting person's spouse transferred 50,092 shares to the Pravin Dugel 2024 Irrevocable Trust (the "Trust") for no consideration. The reporting person is trustee of the Trust and sole beneficiary of the Trust during his lifetime. The reporting person remains the beneficial owner of the securities held by the Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on August 22, 2026. The sales do not represent a discretionary trade by the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.6400 to $10.9000, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3: On August 25, 2026, the reporting person's spouse transferred 50,092 shares to the Pravin Dugel 2024 Irrevocable Trust (the "Trust") for no consideration. The reporting person is trustee of the Trust and sole beneficiary of the Trust during his lifetime. The reporting person remains the beneficial owner of the securities held by the Trust.
Whitehawk Therapeutics, Inc.
Report date June 30, 2021 · Filed July 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,568 |
Reported balance
After 2021-06-30 transaction · row 1
1 source rowRow 1 · 2021-06-30 · Grant · Acquired 6,331 · Balance 12,568 F1: Represents common stock equity awards issued under the Issuer's 2017 Stock Option and Incentive Plan to the non-employee directors of the Issuer in lieu of cash retainer fees pursuant to its non-employee director compensation policy. The price per share was based on the average closing price of the Company's common stock over the quarter ended June 30, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents common stock equity awards issued under the Issuer's 2017 Stock Option and Incentive Plan to the non-employee directors of the Issuer in lieu of cash retainer fees pursuant to its non-employee director compensation policy. The price per share was based on the average closing price of the Company's common stock over the quarter ended June 30, 2021.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
IVERIC bio, Inc.
Report date July 11, 2023 · Filed July 13, 2023
Section 16 reporting ended · disclosed 2023-07-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 1
1 source rowRow 1 · 2023-07-11 · Disposition to issuer · Disposed 203,035 · Balance 0 F1: On July 11, 2023, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated April 28, 2023, by and among IVERIC bio, Inc. ("IVERIC"), Astellas US Holding, Inc., Berry Merger Sub, Inc. ("Merger Sub") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. ("Astellas"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of IVERIC common stock ("Common Stock") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-07-11 · Disposition to issuer · Disposed 8,625 · Balance 0 F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-07-11 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-07-11 · Disposition to issuer · Disposed 37,500 · Balance 0 F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-07-11 · Disposition to issuer · Disposed 70,000 · Balance 0 F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-07-11 · Disposition to issuer · Disposed 27,500 · Balance 0 F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.16 · Expires 2030-03-31 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-07-11 · Disposition to issuer · Disposed 300,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.50 · Expires 2030-12-17 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-07-11 · Disposition to issuer · Disposed 110,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.17 · Expires 2031-05-02 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-07-11 · Disposition to issuer · Disposed 35,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.83 · Expires 2031-12-16 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-07-11 · Disposition to issuer · Disposed 100,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.57 · Expires 2032-12-19 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-07-11 · Disposition to issuer · Disposed 140,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 11, 2023, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated April 28, 2023, by and among IVERIC bio, Inc. ("IVERIC"), Astellas US Holding, Inc., Berry Merger Sub, Inc. ("Merger Sub") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. ("Astellas"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of IVERIC common stock ("Common Stock") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes.
F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU.
F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU.
F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 18, 2022 Filed Dec 20, 2022 19:00 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001410939-22-000135 · wf-form4_167158082880091.xml · derivative · entry 2 Dugel Pravin · CIK 0001700917 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 13,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the units. F2 · derivative.exercise_date: On December 18, 2020, the Reporting Person was granted 55,000 restricted stock units, which vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan. F2 · derivative.expiration_date: On December 18, 2020, the Reporting Person was granted 55,000 restricted stock units, which vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan. Read SEC document |
| December 18, 2022 Filed Dec 20, 2022 19:00 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionCommon Stock | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001410939-22-000135 · wf-form4_167158082880091.xml · nonDerivative · entry 1 Dugel Pravin · CIK 0001700917 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the units. Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 19:48 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionStock Option (right to buy) · Derivative | 8,474 | $10.03 Strike: $10.03 | $84,994.22 |
DisclosureSEC source: 0001410939-22-000116 · wf-form4_166907811502938.xml · derivative · entry 2 Dugel Pravin · CIK 0001700917 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,474 shares Expires 2022-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted on December 30, 2012 and is currently excisable for all shares underlying the option. Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 19:48 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionCommon Stock | 8,474 | $10.03 | $84,994.22 |
DisclosureSEC source: 0001410939-22-000116 · wf-form4_166907811502938.xml · nonDerivative · entry 1 Dugel Pravin · CIK 0001700917 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,473 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2022 Filed May 5, 2022 18:02 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 4,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001410939-22-000061 · wf-form4_165178812088854.xml · derivative · entry 2 Dugel Pravin · CIK 0001700917 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,937 Underlying: Common Stock · 4,313 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F2 · derivative.expiration_date: On May 3, 2021, the Reporting Person was granted 17,250 restricted stock units, which vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan. Read SEC document |
| May 03, 2022 Filed May 5, 2022 18:02 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionCommon Stock | 4,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001410939-22-000061 · wf-form4_165178812088854.xml · nonDerivative · entry 1 Dugel Pravin · CIK 0001700917 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 17:46 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001410939-22-000044 · wf-form4_164919519072734.xml · derivative · entry 2 Dugel Pravin · CIK 0001700917 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F2 · derivative.exercise_date: On April 1, 2020, the Reporting Person was granted 200,000 restricted stock units, which vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2019 Inducement Stock Incentive Plan. F2 · derivative.expiration_date: On April 1, 2020, the Reporting Person was granted 200,000 restricted stock units, which vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2019 Inducement Stock Incentive Plan. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 17:46 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001410939-22-000044 · wf-form4_164919519072734.xml · nonDerivative · entry 1 Dugel Pravin · CIK 0001700917 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,686 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| December 18, 2021 Filed Dec 21, 2021 18:04 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-152295 · tm2135829-8_4seq1.xml · derivative · entry 2 Dugel Pravin · CIK 0001700917 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,250 Underlying: Common Stock · 13,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F2 · derivative.exercise_date: On December 18, 2020, the Reporting Person was granted an award of 55,000 restricted stock units, which vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan. F2 · derivative.expiration_date: On December 18, 2020, the Reporting Person was granted an award of 55,000 restricted stock units, which vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan. Read SEC document |
| December 18, 2021 Filed Dec 21, 2021 18:04 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionCommon Stock | 13,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-152295 · tm2135829-8_4seq1.xml · nonDerivative · entry 1 Dugel Pravin · CIK 0001700917 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,686 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 16:43 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | GrantRestricted Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-151738 · tm2135829-3_4seq1.xml · derivative · entry 2 Dugel Pravin · CIK 0001700917 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F2 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F3 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award in annual installments (on January 2, 2023, January 2, 2024, January 2, 2025 and January 2, 2026). F3 · derivative.expiration_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award in annual installments (on January 2, 2023, January 2, 2024, January 2, 2025 and January 2, 2026). Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 16:43 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $14.83 | $0.00 |
DisclosureSEC source: 0001104659-21-151738 · tm2135829-3_4seq1.xml · derivative · entry 1 Dugel Pravin · CIK 0001700917 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-12-16 F1 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the stock option award will vest with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares, in approximately equal monthly installments through the fourth anniversary of the grant date. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 16:01 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,237 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001104659-21-139120 · tm2132961-1_4seq1.xml · derivative · entry 2 Dugel Pravin · CIK 0001700917 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,237 shares Expires 2022-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted on February 8, 2012 and is currently exercisable for all shares underlying the option. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 16:01 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionCommon Stock | 4,237 | $1.65 | $6,999.52 |
DisclosureSEC source: 0001104659-21-139120 · tm2132961-1_4seq1.xml · nonDerivative · entry 1 Dugel Pravin · CIK 0001700917 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,936 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 21:38 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantCommon Stock | 6,331 | $1.52 | $9,623.12 |
DisclosureSEC source: 0000899243-21-027289 · doc4.xml · nonDerivative · entry 1 Dugel Pravin · CIK 0001700917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,568 F1 · shares: Represents common stock equity awards issued under the Issuer's 2017 Stock Option and Incentive Plan to the non-employee directors of the Issuer in lieu of cash retainer fees pursuant to its non-employee director compensation policy. The price per share was based on the average closing price of the Company's common stock over the quarter ended June 30, 2021. F1 · price: Represents common stock equity awards issued under the Issuer's 2017 Stock Option and Incentive Plan to the non-employee directors of the Issuer in lieu of cash retainer fees pursuant to its non-employee director compensation policy. The price per share was based on the average closing price of the Company's common stock over the quarter ended June 30, 2021. Read SEC document |
| May 03, 2021 Filed May 4, 2021 20:49 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | GrantRestricted Stock Units · Derivative | 17,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-061241 · tm2115186d1_4seq1.xml · derivative · entry 2 Dugel Pravin · CIK 0001700917 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,250 Underlying: Common Stock · 17,250 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock of the Registrant upon vesting of the unit. F3 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date. F3 · derivative.expiration_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| May 03, 2021 Filed May 4, 2021 20:49 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $7.17 | $0.00 |
DisclosureSEC source: 0001104659-21-061241 · tm2115186d1_4seq1.xml · derivative · entry 1 Dugel Pravin · CIK 0001700917 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2031-05-02 F1 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the stock option award will vest with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares, in approximately equal monthly installments through the fourth anniversary of the grant date. Read SEC document |
| April 05, 2021 Filed Apr 5, 2021 21:30 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | SaleCommon Stock | 28,301 | $6.34 | $179,428.34 |
DisclosureSEC source: 0001104659-21-046743 · tm2112227-1_4seq1.xml · nonDerivative · entry 3 Dugel Pravin · CIK 0001700917 · EVP, Chief Strategy & Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,699 F2 · shares: Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the Reporting Person's minimum statutory withholding obligations with respect to the income recognized by the Reporting Person upon the vesting of restricted stock units on April 1, 2021. F3 · price: The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $6.28 to $6.47 on April 5, 2021 on behalf of a group of employees of the Registrant to satisfy the payment of withholding tax liability of such employees. The Reporting Person undertakes to provide upon request by the staff of the Securities Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 21:30 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-046743 · tm2112227-1_4seq1.xml · derivative · entry 5 Dugel Pravin · CIK 0001700917 · EVP, Chief Strategy & Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F5 · derivative.exercise_date: On April 1, 2020, the Reporting Person was granted 20,000 restricted stock units, which vested with respect to 100% of the shares subject to the award on the first anniversary of the grant date on April 1, 2021. F5 · derivative.expiration_date: On April 1, 2020, the Reporting Person was granted 20,000 restricted stock units, which vested with respect to 100% of the shares subject to the award on the first anniversary of the grant date on April 1, 2021. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 21:30 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-046743 · tm2112227-1_4seq1.xml · derivative · entry 4 Dugel Pravin · CIK 0001700917 · EVP, Chief Strategy & Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F4 · derivative.exercise_date: On April 1, 2020, the Reporting Person was granted 200,000 restricted stock units, which vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2019 Inducement Stock Incentive Plan. F4 · derivative.expiration_date: On April 1, 2020, the Reporting Person was granted 200,000 restricted stock units, which vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2019 Inducement Stock Incentive Plan. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 21:30 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-046743 · tm2112227-1_4seq1.xml · nonDerivative · entry 2 Dugel Pravin · CIK 0001700917 · EVP, Chief Strategy & Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 21:30 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-046743 · tm2112227-1_4seq1.xml · nonDerivative · entry 1 Dugel Pravin · CIK 0001700917 · EVP, Chief Strategy & Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| March 31, 2021 Filed Apr 3, 2021 00:30 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantCommon Stock | 6,237 | $1.54 | $9,623.69 |
DisclosureSEC source: 0000899243-21-014674 · doc4.xml · nonDerivative · entry 1 Dugel Pravin · CIK 0001700917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,237 F1 · shares: Represents common stock equity awards issued under the Issuer's 2017 Stock Option and Incentive Plan to the non-employee directors of the Issuer in lieu of cash retainer fees pursuant to its non-employee director compensation policy. The price per share was based on the average closing price of the Company's common stock over the quarter ended March 31, 2021. F1 · price: Represents common stock equity awards issued under the Issuer's 2017 Stock Option and Incentive Plan to the non-employee directors of the Issuer in lieu of cash retainer fees pursuant to its non-employee director compensation policy. The price per share was based on the average closing price of the Company's common stock over the quarter ended March 31, 2021. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 02:44 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 17,857 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0000899243-21-004896 · doc4.xml · derivative · entry 1 Dugel Pravin · CIK 0001700917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,857 Underlying: Common Stock · 17,857 shares Expires 2031-02-01 F1 · derivative.exercise_date: Options shall vest in four equal quarterly installments beginning on February 1, 2021. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 17:49 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | GrantRestricted Stock Units · Derivative | 55,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-138670 · tm2039210d2_4.xml · derivative · entry 2 Dugel Pravin · CIK 0001700917 · EVP, Chief Strategy & Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F3 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date. F3 · derivative.expiration_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 17:49 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | GrantStock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $7.50 | $0.00 |
DisclosureSEC source: 0001104659-20-138670 · tm2039210d2_4.xml · derivative · entry 1 Dugel Pravin · CIK 0001700917 · EVP, Chief Strategy & Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2030-12-17 F1 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the stock option award will vest with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 20:44 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 52,144 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0000899243-20-017777 · doc4.xml · derivative · entry 1 Dugel Pravin · CIK 0001700917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,144 Underlying: Common Stock · 52,144 shares Expires 2030-06-24 F1 · derivative.exercise_date: Options shall vest annually on the earlier of the one year anniversary of the Grant Date or the Company's next annual meeting, subject to director's continued service on the Board at such time. Read SEC document |
| June 18, 2019 Filed Jun 19, 2019 21:25 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 21,400 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0000899243-19-017439 · doc4.xml · derivative · entry 1 Dugel Pravin · CIK 0001700917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,400 Underlying: Common Stock · 21,400 shares Expires 2029-06-18 F1 · derivative.exercise_date: Options shall vest annually on the earlier of the one year anniversary of the Grant Date or the Company's next annual meeting, subject to director's continued service on the Board at such time. Read SEC document |
| October 26, 2018 Filed Nov 16, 2018 21:21 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0000899243-18-029130 · doc4.xml · derivative · entry 1 Dugel Pravin · CIK 0001700917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2028-10-26 F1 · derivative.exercise_date: Options fully vest on the date of grant, subject to the director's service on the Board at such time. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 22:07 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 21,400 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017751 · doc4.xml · derivative · entry 1 Dugel Pravin · CIK 0001700917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,400 Underlying: Common Stock · 21,400 shares Expires 2028-06-20 F1 · derivative.exercise_date: Options shall vest annually on the earlier of the one year anniversary of the Grant Date or the Company's next annual meeting, subject to director's continued service on the Board at such time. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.